These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34675568)

  • 1. Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis.
    Hunter SF; Bindra J; Chopra I; Niewoehner J; Panaccio MP; Wan GJ
    Clinicoecon Outcomes Res; 2021; 13():883-892. PubMed ID: 34675568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost per response analysis of repository corticotropin injection
    Wan GJ; Chopra I; Niewoehner J; Hunter SF
    Drugs Context; 2020; 9():. PubMed ID: 33408750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of Repository Corticotropin Injection versus Standard of Care for the Treatment of Active Rheumatoid Arthritis.
    Bindra J; Chopra I; Niewoehner J; Panaccio M; Wan GJ
    Clinicoecon Outcomes Res; 2021; 13():349-358. PubMed ID: 33986603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Effectiveness for Resolution of Multiple Sclerosis Relapse in a US Health Plan Population.
    Nazareth T; Datar M; Yu TC
    Neurol Ther; 2019 Dec; 8(2):383-395. PubMed ID: 31564036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Acthar Gel versus Standard of Care for the Treatment of Advanced Symptomatic Sarcoidosis.
    Bindra J; Chopra I; Hayes K; Niewoehner J; Panaccio M; Wan GJ
    Clinicoecon Outcomes Res; 2023; 15():739-752. PubMed ID: 37868649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®).
    Gold LS; Suh K; Schepman PB; Damal K; Hansen RN
    Adv Ther; 2016 Aug; 33(8):1279-92. PubMed ID: 27312977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Acthar Gel Versus Standard of Care for the Treatment of Exacerbations in Moderate-to-Severe Systemic Lupus Erythematosus.
    Bindra J; Chopra I; Hayes K; Niewoehner J; Panaccio M; Wan GJ
    Adv Ther; 2023 Jan; 40(1):194-210. PubMed ID: 36266383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse.
    Kaplan J; Miller T; Baker M; Due B; Zhao E
    Front Neurol; 2020; 11():598496. PubMed ID: 33414758
    [No Abstract]   [Full Text] [Related]  

  • 9. Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis.
    Rice JB; Panaccio MP; White A; Simes M; Billmyer E; Downes N; Niewoehner J; Wan GJ
    Neurol Ther; 2021 Jun; 10(1):149-167. PubMed ID: 33170434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications.
    Philbin M; Niewoehner J; Wan GJ
    Adv Ther; 2017 Aug; 34(8):1775-1790. PubMed ID: 28660550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and quality-of-life of treatments for acute relapses of multiple sclerosis: results from a literature review of randomized controlled trials.
    Costello J; Njue A; Lyall M; Heyes A; Mahler N; Philbin M; Nazareth T
    Degener Neurol Neuromuscul Dis; 2019; 9():55-78. PubMed ID: 31308790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence.
    Wan GJ; Niewoehner J; Hayes K
    Clinicoecon Outcomes Res; 2023; 15():499-512. PubMed ID: 37397803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repository corticotropin injection improves quality metrics in an observational study of multiple sclerosis relapse.
    Kaplan J; Miller T; Baker M; Due B; Zhao E
    Neurodegener Dis Manag; 2021 Dec; 11(6):469-476. PubMed ID: 34860120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
    Gani R; Giovannoni G; Bates D; Kemball B; Hughes S; Kerrigan J
    Pharmacoeconomics; 2008; 26(7):617-27. PubMed ID: 18563952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab.
    Knight T; Bond TC; Popelar B; Wang L; Niewoehner JW; Anastassopoulos K; Philbin M
    Clinicoecon Outcomes Res; 2017; 9():271-279. PubMed ID: 28553129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E; Joutseno J; Sumelahti ML
    Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R; Harty G; Wong SL
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results from a multicenter, randomized, double-blind, placebo-controlled study of repository corticotropin injection for multiple sclerosis relapse that did not adequately respond to corticosteroids.
    Wynn D; Goldstick L; Bauer W; Zhao E; Tarau E; Cohen JA; Robertson D; Miller A
    CNS Neurosci Ther; 2022 Mar; 28(3):364-371. PubMed ID: 34984839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
    Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
    Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.
    Yang H; Duchesneau E; Foster R; Guerin A; Ma E; Thomas NP
    J Med Econ; 2017 Oct; 20(10):1056-1065. PubMed ID: 28703659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.